Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinyouli versus rhG-CSF support during concurrent chemoradiotherapy for head and neck, lung, or esophageal cancer
ChiCTR1900026886Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegfilgrastim and Neukast in head and neck cancer (HNC), bronchial carcinoma and esophageal cancer (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Incidence of grade III/IV neutropenia in each cycle of chemotherapy. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
pegfilgrastimNeukast
03
Conditions
head and neck cancer (HNC)bronchial carcinomaesophageal cancer
Beyond the preview
Go deeper on ChiCTR1900026886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026886.